Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
251.27
-1.73 (-0.68%)
At close: Oct 30, 2026, 4:00 PM EDT
251.44
+0.17 (0.07%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Ascendis Pharma Stock Forecast
Stock Price Forecast
According to 22 analysts polled by S&P Global, Ascendis Pharma stock has a consensus rating of "Strong Buy" and an average price target of $304.59. The average 1-year stock price forecast is 21.22% higher than the current stock price, while the lowest is $261.74 (+4.17%) and the highest is $343.18 (+36.58%).
Price Target: $304.59 (+21.22%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 14 | 14 | 16 | 15 | 16 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 18 | 18 | 20 | 20 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Hold Initiates $268 | Hold | Initiates | $268 | +6.66% | Oct 26, 2026 |
| Citi | Citi | Buy Maintains $360 → $330 | Buy | Maintains | $360 → $330 | +31.33% | Oct 26, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $273 | Buy | Maintains | $273 | +8.65% | Oct 26, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $344 | Buy | Reiterates | $344 | +36.90% | Oct 19, 2026 |
| UBS | UBS | Buy Initiates $307 → $269 | Buy | Initiates | $307 → $269 | +7.06% | Oct 14, 2026 |
Financial Forecast
Revenue This Year
1.37B
from 720.13M
Increased by 90.79%
Revenue Next Year
2.01B
from 1.37B
Increased by 46.19%
EPS This Year
10.08
EPS Next Year
8.90
from 10.08
Decreased by -11.72%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.